Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors is a phase 1/2, interventional study registered as NCT04851119 by Children's Oncology Group, with a registry enrolment figure of 147 participants, started 2021-11-08 and due to reach its primary completion in 2028-06-30. Interventions recorded: Biospecimen Collection; Dual X-ray Absorptiometry; Tegavivint; X-Ray Imaging. Conditions listed: Colorectal Carcinoma; Endometrial Carcinoma; Melanoma; Neuroblastoma; Ovarian Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Desmoid Fibromatosis; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Refractory Desmoid Fibromatosis; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Hepatocellular Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Solid Pseudopapillary Neoplasm of the Pancreas; Wilms Tumor. Primary outcome: Frequency of dose limiting toxicities of tegavivint; Frequency of adverse events attributable to tegavivint; Area under the drug concentration curve of tegavivint. Pancreatic eligibility wording from the registry: "IHC showing strong nuclear beta-catenin staining will be accepted for the following tumor types: colorectal carcinoma, melanoma, endometrial cancer, ovarian cancer, neuroblastoma, non-Hodgkin lymphoma, pancreatic ductal adenocarcinoma, and solid pseudopapillary tumor of the pancreas". Sites: United States. No results are recorded here; the registry entry is the source.